MEA Anticoccidial Drugs Market

Middle East and Africa Anticoccidial Drugs Market Size & Growth (2023 to 2028):

The Middle East and Africa market for anticoccidial drugs is estimated to grow from USD 212.49 million in 2023 to USD 248.29 Million by 2028 at a CAGR of 3.16% during the forecast period 2023 to 2028.

Anticoccidial drugs market is expected to be driven by an increase in the incidences of coccidiosis diseases, raising awareness about the importance of maintaining proper hygiene to prevent the spread of the disease in the animals, and increasing research and development activities.

In the recent period, there has been a significant demand for anticoccidial drugs, as the drugs are used to control and prevent the spread of infection due to low maintenance, infected feces, or the ingestion of the infected tissue.

The increasing demand for innovations and advancements in technology to develop the new product provides lucrative growth possibilities for the market growth. Increasing government and private sector investments and funding to research and develop new and innovative drugs are expected to encourage market growth.

Furthermore, growing competition between the market players encourages the key market players to develop innovations that are expected to increase the market growth positively. However, the players are majorly focusing on adopting various marketing strategies such as mergers, collaborations, and acquisitions to preserve their position in the market and develop advancements in the product.

Moreover, the increase in the advancements in veterinary healthcare and rising demand for animal protein and products, which will automatically lead to a rise in the need to export meat and other animal products, are the primary drivers of the anticoccidial drugs market growth.

However, the lack of skilled and trained individuals for manufacturing the drugs with their dosage forms limits the market growth. As well as the approval processes as the process is very tedious and consumes lots of time, the strict government rules and regulations make the entry of the product more difficult, which hinders the market's growth.

Also, the presence of competition in the market with the availability of the various alternative treatment present in the market, such as vaccines and other remedies, is limiting the growth of the anticoccidial drugs market.

This report on the MEA Anticoccidial Drugs Market has been segmented and sub-segmented into the following categories:

By Drug Type: 

• Chemical Derivative Anticoccidials
• Antibiotic anticoccidials
• Ionophore anticoccidials

By Animal Type: 

• Poultry
• Swine
• Fish
• Cattle
• Companion Animal

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA is projected to witness a considerable market share in anticoccidial drugs during the projected period. The market's growth is estimated to be fueled by an increase in the demand for the anticoccidial drug to prevent coccidiosis disease in the animals, improving healthcare infrastructure, and favorable government policies.

 In addition, the countries such as UAE, Saudi Arabia, and South Africa are also expected to hold lucrative growth in the market with the help of government and non-government investments and initiatives in the research and development processes for manufacturing innovative and advanced products.

The South Africa Anticoccidial drugs market held the largest share of the Anticoccidial drugs market in MEA. The adoption of various innovative animal healthcare products led to an increase in the demand for animal products and a rise in the advancements in veterinary healthcare due to the increase in the competition between the market players for the introduction of new products by applying various market strategies to maintain position in the anticoccidial drugs market.

KEY MARKET PLAYERS

Some of the few key players operating in the market are Bayer Healthcare, Zoetis, Elanco, Merial, Merck Animal Healthcare, Virbac, Ceva Santé Animale, Boehringer Ingelheim Animal Health, Novartis Animal Healthcare and Smartvet Inc.,